Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance in elderly/high-risk DLBCL ineligible for autologous HSCT
ChiCTR2100054354Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in diffuse large B-cell lymphoma (DLBCL) comparing Lenalidomide maintenance with Observation (2 arms). Primary endpoint: Progression-free survival. Started Nov 2020; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100054354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054354.